Brind.

Amphastar Pharmaceuticals' outlook was questioned by Wells Fargo, Bank of America, and Needham & Company during an earnings call.

2 reports, 1 independent Updated Aug 14

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Amphastar Pharmaceuticals' outlook was questioned by Wells Fargo, Bank of America, and Needham & Company during an earnings call.

Who's involved

What this event is mainly about

Amphastar Pharmaceuticals Wells Fargo

Keep exploring

The entities involved

Amphastar Pharmaceuticals
publicly traded American pharmaceutical company

Nothing else this week.
Wells Fargo
American multinational banking and financial services company
- Wells Fargo upgraded Sweetgreen stock to overweight from equal weight on September 28, 2026.Mon 16:33
- Capital Research Global Investors acquired and increased its stake in Wells Fargo stock on June 19, 2026.Mon 16:28

Coverage

Newest first; wire copies grouped

Aug 14StockStory5 Insightful Analyst Questions From Amphastar Pharmaceuticals’s Q2 Earnings Call Amphastar Pharmaceuticals delivered a mixed second quarter, with management highlighting BAQSIMI’s strong sales moment
Jul 4Unknown outlet